Industry Case Study — CS-003

Fengate and Clinical Research of West Florida: What a Platform Buyer Needs to Know About a Site

Published November 2026 — In October 2026, Fengate Private Equity took a majority stake in Clinical Research of West Florida, a 30-year-old Tampa Bay site business, with plans to build a regional network around it. The deal is a useful example of what a buyer has to verify before treating a site as a platform.

Executive Summary

A Family-Built Site Becomes a Platform

On October 13, 2026, Fengate Private Equity announced that it had acquired a majority stake in Clinical Research of West Florida (CRWF). Fengate is managing the investment on behalf of the LiUNA Pension Fund of Central and Eastern Canada. The price and the size of the stake were not disclosed.

CRWF was founded in 1995 and has been led by its president, Aydin Keskiner, since 2002. Fengate has said it intends to use the company as the base for a regional site network. This case study looks at what is publicly known about the deal and at the questions any buyer in a similar position has to answer.

Key Findings

30 years
Operating History

CRWF was founded in 1995 by Lynne Merriam. Fengate's announcement describes a 30-year track record.

1,000+
Trials Conducted

The announcement cites more than 1,000 trials across Phase I to IV, for nearly 300 sponsors and CROs.

3
Research Facilities

CRWF operates three facilities across Tampa and Clearwater, including a dedicated Phase I unit.

6
Principal Investigators

The company has six board-certified principal investigators, working in autoimmune, pulmonology, endocrinology, and other areas.

What the Deal Tells Us

The public record covers the structure of the deal, the buyer's plan, and the profile of the business being bought.

1

The Structure

Fengate describes the transaction as a majority stake. Trade coverage of the financing reports that Abacus Finance Group acted as administrative agent and sole lender on the senior debt and also made an equity co-investment. Westcove Partners advised CRWF. Amounts were not disclosed.

2

The Plan

Fengate has said it will invest in talent, site infrastructure, and therapeutic depth, partner with independent sites, and open new sites beyond the company's current area. It is Fengate's second pharma services platform. Its managing director, Maxim Tcherner, said sponsors and CROs increasingly need site partners that can deliver consistent enrollment, quality, and execution at scale.

3

What Is Being Bought

A site business of this kind is made up of its investigators, its coordinators, its patient relationships, and its standing with sponsors. Keskiner described CRWF as a family business built site by site. Those are the assets a platform strategy depends on, and none of them appears on a balance sheet.

4

What the Headline Numbers Do Not Show

Figures such as 1,000 trials and 300 sponsors are cumulative over three decades. They establish credibility, but a buyer also needs the current picture: how many studies are active, how enrollment compares with targets, and how much of the work depends on a small number of investigators or sponsors. That information is not public for this or most other site deals.

What Buyers of Sites Should Check

The same questions apply to any acquisition of a site, whether as a platform or as an add-on.

Recent Performance, Not Lifetime Totals

Ask for enrollment against target, screen failure, and retention on studies from the last two to three years. Lifetime trial counts say little about current capacity.

Dependence on Individuals

Establish how much of the study volume runs through each investigator and how stable the coordinator team is. A site with six investigators is exposed if one of the busiest leaves after the deal.

One Standard for Every Add-On

A regional network is built by adding sites. Each target should be assessed on the same measures as the platform, so that the network's quality is known and not assumed.

Conclusions

The Fengate deal follows a familiar pattern: an established, founder-led site business becomes the base for a regional network backed by institutional capital. The buyer's stated reasoning, that sponsors want consistent execution at scale, is widely shared.

Whether a platform delivers that consistency depends on what was verified before the deal and on how each later acquisition is judged. Nothing in the public record suggests any concern about CRWF. The point is general: site businesses are valued on performance that outsiders can rarely see.

Where SiteScore™ Fits

A Verified View of a Site Before the Deal

SiteScore™ gives investors a standardized way to look at a site. A PreScore, built from public data, allows a quick first pass across possible targets. A Validated Score is checked against the site's own documents and covers five categories: execution, operational depth, market access, financial discipline, and risk and compliance.

Because every site is scored on the same scale, a buyer can compare a platform candidate with later add-ons and track how each one performs after it joins the portfolio.

Sources

This industry case study is based on published announcements and industry research. Figures are reported as stated in the sources below and have not been independently verified by Clinitiative. Companies named are not Clinitiative clients unless stated.

See How SiteScore™ Works

Standardized, document-verified scoring for clinical research sites, used by sponsors, sites, and investors.